Crystals of ibuprofen and tranexamic acid

A 1:1 molar ratio crystal of ibuprofen and tranexamic acid with hydrogen bonds stabilizes the composition, preventing expansion and maintaining solid preparation integrity under high temperatures.

JP7590755B2Active Publication Date: 2024-11-27ZENYAKU KOGYO KK
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2020179864
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-10-27
Publication Date
2024-11-27
Estimated Expiration
2040-10-27

AI Technical Summary

Technical Problem

Solid preparations containing ibuprofen and tranexamic acid expand over time when stored at high temperatures, leading to cracking and reduced marketability due to the incompatibility of the components.

Method used

Forming a new crystal of ibuprofen and tranexamic acid in a 1:1 molar ratio with hydrogen bonds between their carboxylic acid groups, which suppresses expansion by creating a stable crystal structure.

Benefits of technology

The new crystal structure effectively prevents expansion even under high temperature conditions, maintaining the stability and integrity of the solid preparation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590755000005
    Figure 0007590755000005
  • Figure 0007590755000006
    Figure 0007590755000006
  • Figure 0007590755000007
    Figure 0007590755000007
Patent Text Reader

Abstract

To provide a solid preparation containing ibuprofen and tranexamic acid, wherein the preparation resists being expanded even when stored at high temperatures.SOLUTION: Using novel crystals composed of ibuprofen and tranexamic acid can provide a stable solid preparation that resists being expanded even when stored at high temperatures.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a crystal of ibuprofen and tranexamic acid or a method for producing the same. The present invention further relates to a composition, particularly a solid formulation, containing the crystal. [Background technology]

[0002] Ibuprofen is a type of nonsteroidal anti-inflammatory drug (NSAIDs) and is widely used as an anti-inflammatory, analgesic, and antipyretic. Tranexamic acid suppresses inflammation and allergies through its antiplasmin action, so it is used to treat cold symptoms such as sore throat.

[0003] Ibuprofen and tranexamic acid are sometimes combined as active ingredients in pharmaceutical preparations such as anti-inflammatory and antipyretic analgesics, cold medicines, etc. However, solid preparations containing ibuprofen and tranexamic acid tend to expand over time when stored at high temperatures, and in particular, have problems such as cracking of tablets, which significantly reduces their marketability.

[0004] Generally, when two components are incompatible, methods are used to avoid contact between the components or to inhibit the reaction between the two components by adding a third component. Regarding the problem of expansion over time due to ibuprofen and tranexamic acid during high-temperature storage, conventionally, (1) a method of blending the two components so that they do not substantially come into contact with each other (Patent Documents 1 and 2), and (2) a method of blending a third component to inhibit the reaction between the two components, such as blending calcium silicate (Patent Document 3) or an organic acid (Patent Document 4), have been known. In addition, (3) a method of not blending a metal stearate (Patent Document 5) is also known, on the grounds that the expansion is not due to the two components, ibuprofen and tranexamic acid, but is due to the combination of the three components, ibuprofen, tranexamic acid, and magnesium stearate. However, since the mechanism of the above expansion is complex and not yet elucidated, conventional methods have problems such as being unable to completely suppress the expansion and increasing costs due to the increased number of manufacturing steps. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Patent Publication No. 2007-284423 [Patent Document 2] Patent Publication No. 2013-163698 [Patent Document 3] Patent Publication No. 2010-30903 [Patent Document 4] Patent Publication No. 2009-203218 [Patent Document 5] WO2008 / 044331 Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide a solid preparation containing ibuprofen and tranexamic acid, which is suppressed from swelling even when stored under high temperature conditions. [Means for solving the problem]

[0007] Means for Solving the Problems The present inventors have conducted intensive research in order to achieve the above-mentioned object, and as a result have unexpectedly discovered that, although it has been conventionally believed that contact between ibuprofen and tranexamic acid should be avoided, a novel crystal is formed by contacting ibuprofen with tranexamic acid, and by preparing a solid preparation from this novel crystal, expansion can be suppressed even when stored at the above-mentioned high temperatures, thereby completing the present invention.

[0008] The following describes aspects of the present invention. Aspect 1 Ibuprofen and Tranexamic acid and A crystal consisting of. Aspect 2 The ibuprofen and tranexamic acid are present in a 1:1 molar ratio. 2. The crystal according to embodiment 1. Aspect 3 The crystal according to embodiment 1 or 2, wherein ibuprofen and tranexamic acid form a crystal unit cell of four molecules each. Aspect 4 The crystal according to any one of Aspects 1-3, wherein hydrogen bonds are formed between the carboxylic acid group of ibuprofen and the carboxylic acid group of tranexamic acid, and between the carboxylic acid group of ibuprofen and the amino group of tranexamic acid. Aspect 5 The crystal according to any one of aspects 1 to 4, which has an endothermic peak at about 180° C. in differential scanning calorimetry (DSC). Aspect 6 A crystal according to any one of aspects 1 to 5, having a characteristic peak at 2θ=8.4±0.5° in powder X-ray diffraction.

[0009] Aspect 7 A method for producing a crystal of ibuprofen and tranexamic acid, comprising the steps of: The method includes: (1) forming a flowable fluid of ibuprofen by adding a solvent or by heating; (2) mixing the resulting flowable fluid of ibuprofen with tranexamic acid; and (3) forming crystals from the resulting mixture. Aspect 8 A method for producing a crystal of ibuprofen and tranexamic acid, comprising the steps of: A method comprising: (1) obtaining a free-flowing fluid of tranexamic acid; (2) mixing the free-flowing fluid of tranexamic acid with ibuprofen, or with a free-flowing fluid of ibuprofen obtained by adding a solvent or by heating; and (3) forming crystals from the mixture. Aspect 9 9. The method according to claim 7 or 8, comprising drying the resulting mixture in step (3). Aspect 10 The method of any of aspects 7-9, wherein the solvent added to the ibuprofen is selected from ethanol, acetone, dimethylsulfoxide, or a mixture of one or more thereof. Aspect 11 The method of any of aspects 7-10, wherein about 0.1 parts by weight or more, preferably about 0.2 parts by weight or more, of the solvent is added per part by weight of ibuprofen. Aspect 12 The method of any of aspects 7-11, wherein upon heating the ibuprofen, a molten ibuprofen is obtained at about 80° C. or greater. Aspect 13 The method according to any of aspects 8-12, wherein the flowable, fluid tranexamic acid is obtained by adding water to tranexamic acid. Aspect 14 The method according to any one of aspects 7 to 13, further comprising adding a lubricant to the obtained mixture and mixing in step (2) according to aspect 7 or 8. Aspect 15 15. The method according to claim 14, wherein the lubricant is selected from the group consisting of magnesium- or calcium-containing organic acids having 16 to 18 carbon atoms, talc, sucrose fatty acid esters, and hydrogenated fats and oils such as hardened oils. Aspect 16 The method according to any one of aspects 7 to 15, wherein the mixing in step (2) according to aspect 7 or 8 is wet granulation. Aspect 17 The method according to embodiment 16, wherein the wet granulation is mortar granulation, agitation granulation, fluidized bed granulation, tumbling granulation, or extrusion granulation.

[0010] Aspect 18 A method for producing a crystal of ibuprofen and tranexamic acid, comprising the steps of: 1. A method comprising: (1) adding ibuprofen and tranexamic acid to a solvent to obtain a solution or dispersion; (2) spraying and drying the obtained solution or dispersion; or allowing the solution obtained in step (1) to stand, filtering the product obtained after standing, and drying the product. Aspect 19 In step (2), the solution or dispersion is sprayed to form granules, and then dried. The method according to embodiment 18. Aspect 20 20. The method of claim 18 or 19, wherein the solvent is ethanol, water, or a mixture thereof. Aspect 21 The method of any one of aspects 7-20, wherein the ratio of ibuprofen to tranexamic acid is about 1 part by weight:about 10 parts by weight to about 10 parts by weight:about 1 part by weight. Aspect 22 A crystal obtained by the method according to any one of aspects 7-21.

[0011] Aspect 23 A composition comprising a crystal according to any of embodiments 1-6 or a crystal according to embodiment 22. Aspect 24 23. A composition comprising the crystal according to claim 22, in which ibuprofen and tranexamic acid are present in a molar ratio of 1:1, said crystal comprising 80 mol % or more of the raw materials ibuprofen and tranexamic acid, whichever is smaller, in terms of the amount of substance (moles). Aspect 25 25. The composition of embodiment 23 or 24, which is a solid formulation. Aspect 26 The composition according to embodiment 25, wherein the solid formulation is a tablet. Aspect 27 27. The composition of any one of aspects 23-26, which is an anti-inflammatory, antipyretic, or cold remedy. Effect of the Invention

[0012] According to the novel crystals of the present invention, it is possible to provide a solid preparation containing ibuprofen and tranexamic acid, which has excellent stability and is inhibited from expanding even when stored under high temperature conditions. [Brief description of the drawings]

[0013] [Figure 1] 1 shows the structure of the crystal of the present invention prepared in Example 1. [Diagram 2] 1 shows an X-ray diffraction pattern simulated from measurement data obtained during X-ray structure analysis of the crystal of the present invention prepared in Example 1. [Diagram 3] 1 shows a differential scanning calorimetry (DSC) curve of the crystals of the present invention prepared in Example 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Hereinafter, an embodiment of the present invention will be described in detail. The present invention relates to a crystal of ibuprofen and tranexamic acid. The "ibuprofen" in the present invention is a known compound having the chemical name: (2RS)-2-[4-(2-methylpropyl)phenyl]propanoic acid (generic name: ibuprofen), and can be obtained using a commercially available product, or can be produced based on a known method.

[0015] The "tranexamic acid" in the present invention is a known compound having the chemical name: trans-4-(aminomethyl)cyclohexanecarboxylic acid (generic name: tranexamic acid), and can be obtained using a commercially available product or can be produced based on a known method.

[0016] For the crystal of the present invention, X-ray diffraction data was collected from the single crystal obtained in Example 1 described below, and the data was analyzed using the data acquisition and processing software CrysAlis. Pro Data processing and structure analysis were carried out using the structure analysis program package Olex2 and the structure analysis program Mercury3.1. The resulting crystal structure is shown in Figure 1, and the X-ray diffraction pattern simulated from the measured data is shown in Figure 2. The differential scanning calorimetry (DSC) curve of the single crystal obtained in Example 1 is shown in Figure 3.

[0017] From the results of crystal structure analysis and differential scanning calorimetry (DSC), the crystal of the present invention exhibits the following characteristics. Ibuprofen and tranexamic acid are present in a 1:1 molar ratio, and form a crystal unit cell of four molecules of ibuprofen and four molecules of tranexamic acid.

[0018] Hydrogen bonds are formed between the carboxylic acid group of ibuprofen and the carboxylic acid group of tranexamic acid, and between the carboxylic acid group of ibuprofen and the amino group of tranexamic acid. The X-ray diffraction pattern has seven major peaks (2θ=6.3, 8.4, 16.2, 18.5, 19.1, 21.1, 25.6±0.5°).

[0019] In differential scanning calorimetry (DSC), it has an endothermic peak at about 180° C. The heat of fusion peak at about 75° C., which is characteristic of ibuprofen, has disappeared.

[0020] The crystals of ibuprofen and tranexamic acid of the present invention can be produced by the following method AC. Without being bound by theory, it is believed that ibuprofen itself usually forms bimolecular crystals, but during the process of the present invention, ibuprofen in a monomolecular state reacts with tranexamic acid.

[0021] In the method for producing crystals of the present invention, the blending ratio of tranexamic acid to ibuprofen is preferably about 1 part by weight:about 10 parts by weight to about 10 parts by weight:about 1 part by weight, more preferably about 1 part by weight:about 10 parts by weight to about 5 parts by weight:about 1 part by weight, and even more preferably about 1 part by weight:about 3 parts by weight to about 3 parts by weight:about 1 part by weight.

[0022] Method A The method includes: (1) forming a flowable fluid of ibuprofen by adding a solvent or by heating; (2) mixing the resulting flowable fluid of ibuprofen with tranexamic acid; and (3) forming crystals from the resulting mixture.

[0023] In the present invention, "ibuprofen in a flowable fluid state" refers to ibuprofen in a solution, dispersion, wet state (including a paste state) or molten state.

[0024] The solvent used in step (1) is preferably selected from ethanol, acetone, dimethyl sulfoxide, or a mixture of one or more of these, and more preferably ethanol.

[0025] The preferred amount of the solvent used in step (1) is about 0.1 parts by weight or more, more preferably about 0.2 parts by weight or more, per 1 part by weight of ibuprofen. When granulating in step (2), it is preferred to add a solvent in an amount appropriate for the granulation method. For example, when making a paste state by stirring granulation or the like, the preferred amount of the solvent is about 1 part by weight or less, for example, 0.83 parts by weight or less, per 1 part by weight of ibuprofen. For example, when spraying the dispersion by fluidized bed granulation, it is preferred to add the solvent so that the amount of solids in the entire dispersion is 16% by weight or less, taking into account the solubility of ibuprofen.

[0026] In the step (1), when ibuprofen is heated, it is preferable to heat it at a temperature higher than the melting point of ibuprofen. In one preferred embodiment, it is heated at 80° C. or higher to obtain an ibuprofen molten liquid.

[0027] In the step (2), the mixture can be mixed to form a granulated product. The granulation is preferably wet granulation, for example, mortar granulation, stirring granulation, fluidized bed granulation, rolling granulation, extrusion granulation, etc.

[0028] Specific examples of granulation include, but are not limited to, stirring granulation, extrusion granulation, and rolling granulation in which ibuprofen moistened by adding a solvent or ibuprofen in a molten state obtained by heating and melting is mixed with tranexamic acid and granulated, and fluidized bed granulation in which a solvent is added to ibuprofen to form a solution or dispersion, which is then sprayed onto tranexamic acid blown up inside an apparatus.

[0029] Method B A method comprising: (1) obtaining a free-flowing fluid of tranexamic acid; (2) mixing the free-flowing fluid of tranexamic acid with ibuprofen, or with a free-flowing fluid of ibuprofen obtained by adding a solvent or by heating; and (3) forming crystals from the mixture.

[0030] In the present invention, "tranexamic acid in a fluid state having flowability" refers to tranexamic acid in a solution, dispersion, or wet state (including a paste state).

[0031] In step (1), the fluid tranexamic acid is preferably obtained by adding water to tranexamic acid. The preferred amount of water to be added is about 0.2 parts by weight or more per part by weight of tranexamic acid, and for example, about 0.2 to 0.6 parts by weight when a paste is to be formed.

[0032] In step (2), the solvent added to ibuprofen is preferably selected from ethanol, acetone, dimethyl sulfoxide, or a mixture of one or more thereof, and more preferably ethanol. In step (2), granules can be formed while mixing, as in method A. Granulation is preferably wet granulation, and examples thereof include mortar granulation, stirring granulation, fluidized bed granulation, rolling granulation, and extrusion granulation.

[0033] Specific examples of granulation include, but are not limited to, stirring granulation, extrusion granulation, and rolling granulation, in which tranexamic acid moistened by adding water is mixed with ibuprofen, or ibuprofen in a moist or molten state, and granulated, and fluidized bed granulation, in which water is added to tranexamic acid to form a solution or dispersion, which is then sprayed onto ibuprofen blown up inside an apparatus.

[0034] Addition of a third component in Method A and Method B In step (2) of method A and method B, a lubricant can be added to the obtained mixture and mixed. In method B, it is preferable to add a lubricant to a mixture of tranexamic acid in a flowable fluid, preferably tranexamic acid in a wet state, and ibuprofen, and mix the mixture. Granulation can be performed while mixing, and the granulation is preferably wet granulation, such as mortar granulation, stirring granulation, fluidized bed granulation, rolling granulation, and extrusion granulation.

[0035] The lubricant involved in crystal formation is preferably selected from organic acids having 16 to 18 carbon atoms containing magnesium or calcium (e.g., palmitic acid, stearic acid), talc, sucrose fatty acid esters, and hydrogenated fats and oils such as hardened oils, and is more preferably talc or magnesium stearate.

[0036] The amount of the lubricant added is preferably about 0.09 to about 0.36 parts by weight, more preferably about 0.18 parts by weight or more, per part by weight of the granules of ibuprofen and tranexamic acid. In addition, when ibuprofen is mixed with fluid tranexamic acid and the pH becomes acidic, it is preferable that the pH becomes about 6.8 or more by adding a lubricant.

[0037] Other steps related to Method A and Method B The mixture obtained in step (2) of method A and method B is preferably dried as necessary. Drying is preferably performed using a dryer. For example, when a large-sized circulating air dryer with digital temperature display (model: PSD-80, manufacturer: Shimizu Rikagakukiki Seisakusho Co., Ltd.) is used with the inlet air temperature set to 60°C, the temperature near the inlet, which is considered to be the highest, is about 60°C. Therefore, it is estimated that the temperature of the granulated material during drying is at most about 60°C. The preferred temperature of the granulated material during drying varies depending on the type of solvent used in step (1). For example, when ethanol is used, the temperature is preferably about 30 to about 80°C, and more preferably about 40 to about 60°C.

[0038] Method C 1. A method comprising: (1) adding ibuprofen and tranexamic acid to a solvent to obtain a solution or dispersion; (2) spraying and drying the obtained solution or dispersion; or allowing the solution obtained in step (1) to stand, filtering the product obtained after standing, and drying the product.

[0039] The solvent used in step (1) is preferably ethanol, water, or a mixture thereof, more preferably 50% ethanol. In the case of a dispersion, the amount of undissolved ibuprofen or tranexamic acid in the dispersion is preferably an amount that allows spray drying without causing problems such as clogging of the nozzle of the spray dryer, and is preferably about 16% by weight or less, more preferably about 2.4% by weight or less of the total dispersion. In step (2), when the solution or dispersion is sprayed and dried to obtain a granulated product, the solution or dispersion can be sprayed and dried, and granulated simultaneously with drying (e.g., spray drying granulation), or the solution or dispersion can be sprayed, granulated, and then dried (e.g., fluidized bed granulation). The leaving in step (2) can be carried out at room temperature (18-26°C), or can be cooled to about 5°C or below.

[0040] For use as a pharmaceutical, an intermediate composition (which may be in the form of a granule) containing the crystals of the present invention produced from effective amounts of ibuprofen and tranexamic acid as described above can be prepared, and other active ingredients and additives other than those involved in crystal formation, such as excipients, binders, adsorbents, disintegrants, lubricants, coating agents, flavorings, and fragrances, can be added to the intermediate composition to form a final composition, which can be used as a pharmaceutical preparation, particularly a solid preparation.

[0041] Examples of the dosage form of the solid preparation include capsules, pills, granules, tablets, powders, etc., and tablets are particularly preferred. The solid preparation may be coated with sugar coating, film coating, etc. In the case of tablets, they can be produced by compressing and molding the above composition by a known method.

[0042] By preparing a solid preparation using the crystals of ibuprofen and tranexamic acid of the present invention, expansion can be suppressed even when stored under high temperature conditions. In contrast, in conventional preparations, both ibuprofen and tranexamic acid exist in a free state that is not involved in the formation of crystals, and it is presumed that they react with each other during storage at high temperatures, causing expansion.

[0043] As shown in the following test examples, the higher the crystal formation rate of the solid preparation prepared using the intermediate composition containing the crystal of the present invention produced by the above methods A to C, the more suppressed the expansion when stored at 50°C for 2 months. The crystal formation rate was determined by calculating the proportion of ibuprofen involved in crystal formation from the amount of ibuprofen in a free state not involved in the formation of the crystal of the present invention contained in the sample after crystal production, calculated from the results of differential scanning calorimetry (DSC), using the smaller amount (mol) of raw material ibuprofen or tranexamic acid as the standard, and the standard amount of raw material ibuprofen. An example of calculating the crystal formation rate is shown in the following test example, but the calculation method is not limited thereto.

[0044] The intermediate compositions containing the crystals of the present invention produced by the above methods A to C preferably contain the crystals in an amount of 80 mol % or more, more preferably 85 mol % or more, even more preferably 90 mol % or more, and even more preferably 95 mol % or more, based on the smaller of the amounts (moles) of the raw materials ibuprofen and tranexamic acid.

[0045] The solid preparation of the present invention may contain other active ingredients and additives other than those involved in crystal formation, such as excipients, binders, adsorbents, disintegrants, lubricants, coating agents, flavoring agents, and fragrances, examples of which include, but are not limited to, the following:

[0046] Examples of excipients include sugars such as lactose, sucrose, reduced maltose syrup, and trehalose, starches, crystalline cellulose, sugar alcohols, and light anhydrous silicic acid. Examples of binders include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, and pullulan. Examples of adsorbents include light anhydrous silicic acid, crystalline cellulose, crospovidone, hydrated silicon dioxide, magnesium aluminometasilicate, aluminum silicate, calcium silicate, carmellose calcium, magnesium silicate, magnesium carbonate, and croscarmellose sodium. Examples of disintegrants include carmellose, carmellose calcium, low-substituted hydroxypropylcellulose, crospovidone, and croscarmellose sodium. Examples of lubricants include glycerin fatty acid esters, sucrose fatty acid esters, hardened oils, stearic acid, magnesium stearate, calcium stearate, and talc. Examples of coating agents include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan, methylcellulose, ethylcellulose, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, etc. Examples of flavoring agents include acesulfame potassium, aspartame, sucralose, stevia extract, etc.

[0047] The solid preparation of the present invention may contain an active ingredient other than ibuprofen or tranexamic acid, such as the following medicinal ingredients, either as a single ingredient or in combination of two or more ingredients. Note that the following are examples and are not intended to be limiting. Antipyretics and analgesics: Aspirin, aspirin aluminum, sazapirin, ethenzamide, salicylamide, acetaminophen, isopropylantipyrine, lactylphenetidine, loxoprofen, etc. Stimulants: Caffeine, anhydrous caffeine, sodium benzoate caffeine, etc. Antihistamines: Azelastine hydrochloride, isothipendyl hydrochloride, clemastine fumarate, ketotifen fumarate, diphenylpyraline hydrochloride, diphenhydramine hydrochloride, difeterol hydrochloride, triprolidine hydrochloride, tripelennamine hydrochloride, thonzylamine hydrochloride, fenethazine hydrochloride, methdilazine hydrochloride, diphenhydramine salicylate, carbinoxamine diphenyl disulfonate, alimemazine tartrate, diphenhydramine tannate, diphenylpyraline teoclate, mebhydroline napadisilate, promethazine methylenedisalicylate, carbinoxamine maleate, dl-chlorpheniramine maleate, mequitazine, difeterol phosphate, fexofenadine, etc. Cough suppressants: Alloclamide hydrochloride, cloperastine hydrochloride, carbetapentane citrate, tipepidine citrate, dibunate sodium, dextromethorphan hydrobromide, dextromethorphan phenolphthaline salt, tipepidine hibenzate, cloperastine fendizoate, codeine phosphate, dihydrocodeine phosphate, noscapine hydrochloride, noscapine, dl-methylephedrine hydrochloride, dl-methylephedrine saccharin salt, etc. Expectorants: Potassium guaiacolsulfonate, guaifenesin, bromhexine hydrochloride, ambroxol hydrochloride, carbocisteine, etc. Herbal medicines: Herbal medicines such as radish root, cinnamon bark, ginger, garlic, ephedra, nandina, scutellaria, onji, licorice, bellflower, apricot kernel, pinecone, rhizome, rhizome, rhizome, saxifrage, senega, fritillary, fennel, phellodendron bark, coptis, zedoary, chamomile, gentian, bezoar, rhizome, sophora rhizome, clove, chinpi, byadenito, chikusetsu ginseng (bamboo joint ginseng), and carrot, and their extracts (extracts, tinctures, dried extracts, etc.), etc. Gastric mucosa protectant: Glycine, synthetic aluminum silicate, aluminum magnesium metasilicate, vitamin U, copper chlorophyllin sodium, sucralfate, copper chlorophyllin potassium, cetraxate hydrochloride, gefarnate, sodium azulene sulfonate, aldioxa, sofalcone, teprenone, methylmethionine sulfonium chloride, troxipide, L-glutamine, magnesium oxide, hydrotalcite, magnesium hydroxide, anhydrous calcium hydrogen phosphate, precipitated calcium carbonate, sodium bicarbonate, magnesium carbonate, calcium carbonate, dried magnesium hydroxide, Scopolia extract, H2 blockers (ranitidine, cimetidine, roxatidine, famotidine), etc. Vitamins: Vitamin A, cod liver oil, vitamin B1, vitamin B2, vitamin B6, vitamin B 12 , vitamin C, calcium ascorbate, vitamin D, vitamin E, calcium tocopherol succinate, etc.

[0048] Furthermore, the dosage of the solid preparation of the present invention to a patient may be appropriately determined based on the patient's sex, age, weight, symptoms, administration method, number of administrations, administration time, etc. For example, tranexamic acid is preferably administered at 10 to 3000 mg per day, more preferably at 400 to 750 mg, and particularly preferably at 750 mg. Ibuprofen is preferably administered at 30 to 2000 mg per day, more preferably at 200 to 600 mg, and particularly preferably at 600 mg.

[0049] The solid preparation of the present invention is preferably used as an anti-inflammatory, antipyretic, analgesic or cold remedy.

[0050] The present invention will be described below with reference to Comparative Examples, Examples, Formulation Examples, and Test Examples, but the present invention should not be limited thereto. Unless otherwise specified, the experimental procedures were carried out at room temperature (18-26°C). In addition, for ibuprofen, "IBUPROFEN" obtained from ALBEMRLE CORPORATION was used, for tranexamic acid, "Tranexamic Acid" obtained from Kyowa Pharma Chemical Co., Ltd. was used, and for talc, "Food Additive Talc MS" obtained from Nippon Talc Co., Ltd. was used. EXAMPLES

[0051] Comparative Example Comparative Example 1 7.2 g of ibuprofen and 15.0 g of tranexamic acid were mixed uniformly using a mortar and pestle, and then compressed at 200 kg / cm using a tablet press (product name: Riken Hydraulic Power, model: P-1B, manufacturer: Riken Seiki Co., Ltd.) equipped with a 13 mm diameter punch. 2 The tablets were compressed at a compression pressure of 1000 g each to obtain tablets weighing 2 g each. Comparative Example 2 7.2 g of ibuprofen, 15.0 g of tranexamic acid, and 4.0 g of talc were mixed uniformly using a mortar and pestle, and then tablets were obtained under the same tableting conditions as in Comparative Example 1. Comparative Example 3 5.0 g of ibuprofen and 5.0 g of tranexamic acid were mixed uniformly using a mortar and pestle, and then tablets were obtained under the same tableting conditions as in Comparative Example 1.

[0052] Working Example Example 1 400 g of 50 w / w% ethanol aqueous solution was prepared in a 500 mL glass beaker, and then 10.0 g of ibuprofen and 10.0 g of tranexamic acid were added and stirred and dissolved using a stirrer (product name: MAGNETIC STIRRER, model: RP-1DR, manufacturer: AS ONE Co., Ltd.). This solution was left to stand at 5°C for one week to precipitate crystals. The solution containing the precipitated crystals was filtered using filter paper (product name: FILTER PAPER, grade: 131, size: 95 mm, manufacturer: Advantec Co., Ltd.), and then dried for one hour using a dryer (product name: digital temperature display large circulation type dryer, model: PSD-80, manufacturer: Shimizu Rikagakukiki Seisakusho Co., Ltd.) with the supply air temperature set to 60°C, to obtain single crystals consisting of both ibuprofen and tranexamic acid.

[0053] Example 2 20.0 g of ibuprofen was placed in a 300 mL glass beaker and melted by heating in a thermostatic water bath (product name: WATER BATH, model: TBM206AA, manufacturer: Yamato Scientific Co., Ltd.) set at 100° C., and when the ibuprofen molten liquid was at 81° C., 20.0 g of tranexamic acid was added and stirred to obtain a mixed powder. This mixed powder was mixed and crushed using a mortar and pestle, and tablets were obtained under the same tableting conditions as in Comparative Example 1.

[0054] Example 3 After putting 7.2 g of ibuprofen into a mortar, 0.7 g of ethanol was added and kneaded with a pestle. After adding 15.0 g of tranexamic acid to this kneaded product and granulating it with a pestle, it was dried for 2 hours using a dryer (product name: digital temperature display large circulating air blower dryer, model: PSD-80, manufacturer: Shimizu Rikagakukiki Seisakusho Co., Ltd.) with an inlet air temperature set to 60°C. After mixing and pulverizing this dried product using a mortar and pestle, tablets were obtained under the same tableting conditions as in Comparative Example 1. Example 4 7.2 g of ibuprofen was placed in a mortar, 1.5 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 15.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 5 7.2 g of ibuprofen was placed in a mortar, 2.9 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 15.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 6 7.2 g of ibuprofen was placed in a mortar, 3.6 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 15.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 7 7.2 g of ibuprofen was placed in a mortar, 6.0 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 15.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3.

[0055] Example 8 5.0 g of ibuprofen was placed in a mortar, 2.5 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 50.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 9 10.0 g of ibuprofen was placed in a mortar, 5.0 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 30.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 10 10.0 g of ibuprofen was placed in a mortar, 5.0 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 20.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 11 10.0 g of ibuprofen was placed in a mortar, 5.0 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 10.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 12 20.0 g of ibuprofen was placed in a mortar, 10.0 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 10.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 13 30.0 g of ibuprofen was placed in a mortar, 15.0 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 10.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 14 50.0 g of ibuprofen was placed in a mortar, 25.0 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 10.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 15 50.0 g of ibuprofen was placed in a mortar, 25.0 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 5.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3.

[0056] Example 16 7.2 g of ibuprofen was put into a mortar, 1.5 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 15.0 g of tranexamic acid was added to the kneaded mixture and granulated with a pestle, and then 4.0 g of talc was added and further granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 17 7.2g of ibuprofen was put into a mortar, 3.6g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. 15.0g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. Then, 2.0g of talc was added, and the mixture was further granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3.

[0057] Example 18 180.0 g of ibuprofen was put into a stirring granulator (product name: high speed mixer, model: LFS-GS-1J, manufacturer: Fukae Kogyo Co., Ltd.), and then 75.0 g of ethanol was added and kneaded until a paste was formed. 375.0 g of tranexamic acid was added to the kneaded mixture and granulated. After granulation, tablets were obtained under the same conditions as in Example 3.

[0058] Example 19 10.0 g of ibuprofen was placed in a mortar, 4.5 g of dimethyl sulfoxide was added, and the mixture was kneaded with a pestle until it became a paste. 10.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 20 10.0 g of ibuprofen was placed in a mortar, 14.0 g of acetone was added, and the mixture was kneaded with a pestle until it became a paste. 10.0 g of tranexamic acid was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3.

[0059] Example 21 400 g of 50 w / w% ethanol aqueous solution was prepared in a 500 mL glass beaker, and then 10.0 g of ibuprofen and 10.0 g of tranexamic acid were added and stirred and dissolved using a stirrer (product name: MAGNETIC STIRRER, model: RP-1DR, manufacturer: AS ONE Co., Ltd.). This solution was spray-dried using a spray dryer (product name: spray dryer, model: B-290, manufacturer: Nippon Buchi Co., Ltd.) under conditions of an inlet air temperature of 70°C and an exhaust air temperature of 40°C. The powder after spray drying was mixed uniformly using a mortar and pestle, and tablets were obtained under the same tableting conditions as in Comparative Example 1. Example 22 400 g of ethanol was added to a 500 mL glass beaker, then 10.0 g of ibuprofen and 10.0 g of tranexamic acid were added, and the mixture was stirred with a stirrer (product name: MAGNETIC STIRRER, model: RP-1DR, manufacturer: AS ONE Co., Ltd.) to obtain a dispersion. This dispersion was spray-dried under the same conditions as in Example 21, and the powder after spray drying was mixed uniformly using a mortar and pestle, and tablets were obtained under the same tableting conditions as in Comparative Example 1. Example 23 400 g of purified water was placed in a 500 mL glass beaker, followed by addition of 10.0 g of ibuprofen and 10.0 g of tranexamic acid, and stirring with a stirrer (product name: MAGNETIC STIRRER, model: RP-1DR, manufacturer: AS ONE Co., Ltd.) to obtain a dispersion. This dispersion was spray-dried under the same conditions as in Example 21, and the powder after spray drying was mixed uniformly using a mortar and pestle, and tablets were obtained under the same tableting conditions as in Comparative Example 1. Example 24 400 g of 50 w / w% ethanol aqueous solution was prepared in a 500 mL glass beaker, and then 50.0 g of ibuprofen and 50.0 g of tranexamic acid were added and stirred with a stirrer (product name: MAGNETIC STIRRER, model: RP-1DR, manufacturer: AS ONE Co., Ltd.) to obtain a dispersion. This dispersion was spray-dried under the same conditions as in Example 21, and the powder after spray drying was mixed uniformly using a mortar and pestle, and tablets were obtained under the same tableting conditions as in Comparative Example 1.

[0060] Example 25 15.0 g of tranexamic acid was placed in a mortar, 9.2 g of purified water was added, and the mixture was kneaded with a pestle until it became a paste. 7.2 g of ibuprofen was added to the kneaded mixture, and the mixture was granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 26 15.0g of tranexamic acid was put into a 100mL glass beaker, 9.2g of purified water was added, and the mixture was stirred with a stirring rod until it became a paste. Next, 7.2g of ibuprofen was put into a mortar, and then 1.5g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste. The stirred product of tranexamic acid was added to the kneaded product of ibuprofen, and granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 27 15.0 g of tranexamic acid was put into a 100 mL glass beaker, 9.2 g of purified water was added, and the mixture was stirred with a stirring rod until it became a paste (pH was 7.7). Next, 7.2 g of ibuprofen was put into a mortar, and then 1.5 g of ethanol was added, and the mixture was kneaded with a pestle until it became a paste (pH was 3.6). The mixture of tranexamic acid was added to the kneaded ibuprofen and granulated with a pestle (pH was 6.7), and then 4.0 g of talc was added and further granulated with a pestle (pH was 6.9). After granulation, tablets were obtained under the same conditions as in Example 3. Example 28 15.0 g of tranexamic acid was put into a mortar, 9.2 g of purified water was added, and the mixture was kneaded with a pestle until it became a paste. 7.2 g of ibuprofen was added to the kneaded mixture, which was then granulated with a pestle. Then, 2.0 g of talc was added, and the mixture was further granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 29 15.0 g of tranexamic acid was put into a mortar, 9.2 g of purified water was added, and the mixture was kneaded with a pestle until it became a paste (pH 7.3). 7.2 g of ibuprofen was added to the kneaded mixture (pH 6.6), and the mixture was granulated with a pestle. Next, 4.0 g of talc was added (pH 6.8), and the mixture was further granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 30 15.0 g of tranexamic acid was put into a mortar, 9.2 g of purified water was added, and the mixture was kneaded with a pestle until it became a paste. 7.2 g of ibuprofen was added to the kneaded mixture, and the mixture was granulated with a pestle. Then, 8.0 g of talc was added, and the mixture was further granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 31 15.0 g of tranexamic acid was put into a mortar, 9.2 g of purified water was added, and the mixture was kneaded with a pestle until it became a paste (pH 7.5). 7.2 g of ibuprofen was added to the kneaded mixture (pH 6.6), and the mixture was granulated with a pestle. Next, 4.0 g of magnesium stearate was added (pH 7.6), and the mixture was further granulated with a pestle. After granulation, tablets were obtained under the same conditions as in Example 3. Example 32 15.0 g of tranexamic acid was put into a mortar, 9.2 g of purified water was added, and the mixture was kneaded with a pestle until it became a paste (pH 7.7). 7.2 g of ibuprofen was added to the kneaded mixture, and the mixture was granulated with a pestle (pH 6.8), and then 4.0 g of calcium stearate was added and the mixture was further granulated with a pestle (pH 7.0). After granulation, tablets were obtained under the same conditions as in Example 3. Example 33 15.0g of tranexamic acid was put into a mortar, 9.2g of purified water was added, and the mixture was kneaded with a pestle until it became a paste (pH 7.7). 7.2g of ibuprofen was added to the kneaded mixture and granulated with a pestle (pH 6.8), and then 4.0g of sucrose fatty acid ester was added and further granulated with a pestle (pH 6.9). After granulation, tablets were obtained under the same conditions as in Example 3. Example 34 15.0 g of tranexamic acid was put into a mortar, 9.2 g of purified water was added, and the mixture was kneaded with a pestle until it became a paste (pH 7.7). 7.2 g of ibuprofen was added to the kneaded mixture, and the mixture was granulated with a pestle (pH 6.8), and then 4.0 g of hardened oil was added and the mixture was further granulated with a pestle (pH 6.8). After granulation, tablets were obtained under the same conditions as in Example 3.

[0061] Formulation examples Formulation A 144.0 g of ibuprofen was put into a stirring granulator (product name: high speed mixer, model: LFS-GS-1J, manufacturer: Fukae Kogyo Co., Ltd.), 60.0 g of ethanol was added and kneaded until a paste was formed, after which 300.0 g of tranexamic acid was added and further granulated. The granules were dried for 2 hours using a dryer (product name: digital temperature display large circulation type dryer, model: PSD-80, manufacturer: Shimizu Rikagaku Kikai Seisakusho Co., Ltd.) with the supply air temperature set to 60°C, and then granulated using a granulator equipped with a 14 mesh (product name: New Speed ​​Mill, model: ND-02S, manufacturer: Okada Seiko Co., Ltd.). The sized product was mixed with 483.1 g of crystalline cellulose, 28.0 g of croscarmellose sodium, 8.0 g of light anhydrous silicic acid, and 8.9 g of magnesium stearate in a mixer (product name: V-type mixer, model: V-5, manufacturer: Tokuju Manufacturing Co., Ltd.). The mixture was tableted using a tablet press (product name: PICCOLA, model: B / 10, manufacturer: Estec Co., Ltd.) equipped with a pestle with a diameter of 9 mm at a tableting speed of 30 rpm and a tableting pressure of 11 kN, to obtain tablets weighing 0.27 g each. Formulation B 144.0 g of ibuprofen was put into a stirring granulator (product name: high-speed mixer, model: LFS-GS-1J, manufacturer: Fukae Kogyo Co., Ltd.), 60.0 g of ethanol was added, and the mixture was kneaded until it became a paste, after which 300.0 g of tranexamic acid was added and granulated. Next, 80.0 g of talc was added and granulated for another 1 minute. This granulated product was dried and sized under the same conditions as those for Formulation A. This sized product was mixed with 403.1 g of crystalline cellulose, 28.0 g of croscarmellose sodium, 8.0 g of light anhydrous silicic acid, and 8.9 g of magnesium stearate in a mixer (product name: V-type mixer, model: V-5 type, manufacturer: Tokuju Kogyo Co., Ltd.) and mixed. This mixture was tableted under the same tableting conditions as those for Formulation A to obtain tablets of the same weight.

[0062] Test Example Test Example A Structural analysis and differential scanning calorimetry (DSC) of crystals of ibuprofen and tranexamic acid. The single crystal of Example 1 was cut to an appropriate size on a glass plate using a cutter, immersed in oil for handling (product name: Paratone-N, manufacturer: Chevron Corporation), then scooped up with a Dual-Thickness-MicroloopsLD (grade: 75 μmφ, manufacturer: MiTeGen Co., Ltd.), and frozen in a nitrogen-blow cryogenic device to prepare a sample. X-ray diffraction data was collected from the prepared sample using a single crystal X-ray diffractometer (product name: XtaLAB Synergy-S, manufacturer: Rigaku Corporation) under conditions of a Cu source, a voltage of 50 kV, a current of -1 mA, and a measurement temperature of -173°C, and the data was analyzed using the data measurement and processing software CrysAlis. Pro The structure was refined using the structure analysis program package Olex2. The resulting crystallographic data are shown in Table 1. The crystal structure (hydrogen atoms omitted) is shown in Figure 1, and the X-ray diffraction pattern simulated from the measured data is shown in Figure 2 (program used: Mercury3.1).

[0063] Crystal structure analysis confirmed that in the crystals of the present invention, ibuprofen and tranexamic acid are present in a molar ratio of 1:1, four molecules each of ibuprofen and tranexamic acid form a crystal unit cell, and hydrogen bonds are formed between the carboxylic acid group of ibuprofen and the carboxylic acid group of tranexamic acid, and between the carboxylic acid group of ibuprofen and the amino group of tranexamic acid.

[0064] The X-ray diffraction pattern simulated from the measured data showed seven major peaks (2θ = 6.3, 8.4, 16.2, 18.5, 19.1, 21.1, 25.6 ± 0.5°).

[0065] The single crystal of Example 1 was weighed in an aluminum cell and measured using a differential scanning calorimeter (product name: DSC-60A, manufacturer: Shimadzu Corporation) under nitrogen at a heating rate of 10°C / min and a measurement temperature of 30 to 350°C. As a result, the curve shown in Figure 3 was obtained, and an endothermic peak was confirmed near 180°C. This endothermic peak was not observed in ibuprofen or tranexamic acid alone, and was therefore considered to be an endothermic peak related to the melting of the crystal of the present invention. It was confirmed that the endothermic peak near 75°C related to the melting of ibuprofen had disappeared.

[0066] [Table 1]

[0067] Test Example B Powder X-ray diffraction measurement (PXRD) The samples before tableting in Comparative Examples 1 and 3 and Examples 1 to 34 were measured using a powder X-ray diffractometer (product name: MiniFlexII, manufacturer: Rigaku Corporation) under conditions of a Cu source, a voltage of 30 kV, a current of 15 mA, a scan speed of 2θ = 4.00° / min, a sampling width of 2θ = 0.02°, and a scan range of 2θ = 4.00 to 40.00°.

[0068] As a result, in Examples 1 to 34, the same X-ray diffraction patterns as in FIG. 2 were observed, and it was confirmed that the crystals of the present invention had a peak at 2θ=8.4±0.5°, which is a peak characteristic of the crystals of the present invention (Table 2). On the other hand, the X-ray diffraction patterns of Comparative Examples 1 and 3 did not show a peak at 2θ=8.4±0.5°. From the above results, it was considered that the arrangement of atoms and molecules forming the crystals was different between Examples 1 to 34 and Comparative Examples 1 and 3, and that Examples 1 to 34 contained the crystals of the present invention.

[0069] [Table 2]

[0070] Test Example C Differential Scanning Calorimetry (DSC) Approximately 10 mg of the samples before tableting in Comparative Example 3 and Examples 1-13, 16-25, and 28-30 was weighed into an aluminum cell and measured using a differential scanning calorimeter (product name: DSC-60A, manufacturer: Shimadzu Corporation) under nitrogen at a heating rate of 10°C / min and a measurement temperature of 30 to 350°C. As a result, in Examples 1-13, 16-25, and 28-30, a decrease in the endothermic amount associated with the melting of ibuprofen at around 75°C and an endothermic peak associated with the melting of the crystals of the present invention at around 180°C were observed, but in Comparative Example 3, no endothermic peak was observed at around 180°C (Table 3). From the above results, it was considered that Examples 1-13, 16-25, and 28-30 contained the crystals of the present invention.

[0071] [Table 3]

[0072] Test Example D Calculation of crystal formation rate For the samples of Comparative Examples 1 and 2 and Examples 2, 4-13, 16-19, 21-23, 26, and 28-32 before tableting, the endothermic heat at the time of melting of ibuprofen (free ibuprofen) not involved in the formation of the crystals of the present invention was measured using a differential scanning calorimeter (product name: DSC-60A, manufacturer: Shimadzu Corporation), and the formation rate of the crystals of the present invention was calculated by the method shown below. In the crystals of the present invention, ibuprofen and tranexamic acid are present in a molar ratio of 1:1. (1) The endothermic heat (approximately 119.47 J / g) at the time of melting (around 75°C) obtained from the measurement results of ibuprofen alone was used as the reference endothermic heat of free ibuprofen. (2) The endothermic heat near 75°C obtained from the measurement results of the sample was regarded as the endothermic heat of free ibuprofen in the sample. (3)(1) The reference endothermic heat of free ibuprofen was multiplied by the weight ratio of ibuprofen contained in the sample (ibuprofen weight / sample weight) to calculate the endothermic heat when all of the ibuprofen in the sample is free ibuprofen. (4) When the amount (mol) of ibuprofen in the sample was equal to or smaller than the amount (mol) of tranexamic acid, the amount (mol) of ibuprofen was used as the reference amount, and the proportion of free ibuprofen in the sample was calculated from (2) and (3) (endothermic amount of free ibuprofen in the sample / endothermic amount assuming that all of the ibuprofen in the sample is free ibuprofen = free ibuprofen proportion). (5) When the amount (mol) of ibuprofen in the sample is greater than the amount (mol) of tranexamic acid, the amount (mol) of tranexamic acid was used as the reference amount, and the endothermic heat calculated in (3) was multiplied by the ratio of ibuprofen minus the reference amount ((amount of ibuprofen in the sample-reference amount) / amount of ibuprofen in the sample) and subtracted from the endothermic heat measured in (2) to calculate the endothermic heat of the reference amount of free ibuprofen. (6) When the amount (mol) of ibuprofen in the sample was greater than the amount (mol) of tranexamic acid, the amount (mol) of tranexamic acid was used as the reference amount, and the endothermic heat calculated in (3) was multiplied by the ratio of the reference amount (reference amount / amount of ibuprofen in sample) to calculate the endothermic heat if all of the ibuprofen in the reference amount was free ibuprofen. (7) When the amount (mol) of ibuprofen in the sample was greater than the amount (mol) of tranexamic acid, the proportion of free ibuprofen in the reference amount of ibuprofen was calculated from (5) and (6) (endothermic heat of free ibuprofen in the reference amount of ibuprofen in the sample / endothermic heat assuming that all of the reference amount of ibuprofen is free ibuprofen = free ibuprofen proportion). (8) From the percentage of free ibuprofen calculated in (4) or (7), the percentage of ibuprofen involved in crystal formation in the reference amount of ibuprofen was calculated, and the crystal formation rate of the present invention was calculated ((1-free ibuprofen percentage) x 100 = crystal formation rate (%)).

[0073] Test Example E Calculation of tablet thickness change rate (evaluation of expansion suppression effect) Three tablets of each tablet prepared in Comparative Examples 1 and 2 and Examples 2, 4-13, 16-19, 21-23, 26, and 28-32 were filled into a standard tablet bottle (5K), sealed with a metal cap, and then stored in a constant temperature bath (product name: programmable low-temperature incubator, model: IQ820, manufacturer: Yamato Scientific Co., Ltd.) at 50°C for two months. The tablet thickness change rate (%) was calculated according to the following formula from the thickness of the tablet immediately after production and the thickness of the tablet after storage, which were measured with a micrometer (product name: standard outside micrometer M300, model: M320-25AA, manufacturer: Mitutoyo Co., Ltd.). Tablet thickness change rate (%) = {(tablet thickness after storage) - (tablet thickness immediately after production)} / (tablet thickness immediately after production) x 100 The crystal formation rate calculated in Test Example D and the tablet thickness change rate calculated in Test Example E are shown in Table 4. In Comparative Examples 1 and 2, the formation of the crystals of the present invention was hardly observed, whereas in Examples 2, 4-13, 16-19, 21-23, 26, and 28-32, the crystal formation rate was high, at 80% or more. In Comparative Examples 1 and 2, the tablet thickness change rate was 23.7% and 31.1% when stored at 50 ° C for 2 months, and the tablet expansion was observed, whereas in Examples 2, 4-13, 16-19, 21-23, 26, and 28-32, the tablet thickness change rate was less than 5%, and the tablet expansion was suppressed. From the above results, it was considered that Examples 2, 4-13, 16-19, 21-23, 26, and 28-32 were stable solid preparations containing a high proportion of the crystals of the present invention and suppressing expansion even under high temperature conditions and long-term storage. Furthermore, a correlation was observed in which the higher the crystal formation rate, the lower the rate of change in tablet thickness.

[0074] [Table 4] [Industrial Applicability]

[0075] The present invention uses a novel crystal of ibuprofen and tranexamic acid to provide a stable solid preparation that suppresses expansion during high-temperature storage, which is a concern when ibuprofen and tranexamic acid are simultaneously blended. It is known that preparations containing ibuprofen and tranexamic acid can obtain additional effects such as enhanced efficacy and reduced side effects in addition to the pharmacological effects of these ingredients, and the present invention makes it possible to provide such a useful pharmaceutical preparation as a solid preparation that is stable even under high-temperature conditions and for long-term storage, making it extremely useful in the pharmaceutical industry.

Claims

1. Ibuprofen and Tranexamic acid and A crystal consisting of.

2. The ibuprofen and tranexamic acid are present in a 1:1 molar ratio. The crystal described in claim 1.

3. The crystal according to claim 1 or 2, wherein ibuprofen and tranexamic acid form a crystal unit cell of four molecules each.

4. The crystal according to any one of claims 1 to 3, wherein hydrogen bonds are formed between the carboxylic acid group of ibuprofen and the carboxylic acid group of tranexamic acid, and between the carboxylic acid group of ibuprofen and the amino group of tranexamic acid.

5. The crystal according to any one of claims 1 to 4, which has an endothermic peak at about 180°C in differential scanning calorimetry (DSC).

6. The crystal according to any one of claims 1 to 5, having a characteristic peak at 2θ = 8.4 ± 0.5° in powder X-ray diffraction.

7. A method for producing a crystal of ibuprofen and tranexamic acid, comprising the steps of:

1. A method comprising: (1) forming a flowable fluid of ibuprofen by adding a solvent or by heating; (2) mixing the resulting flowable fluid of ibuprofen with tranexamic acid; and (3) forming crystals from the resulting mixture.

8. A method for producing a crystal of ibuprofen and tranexamic acid, comprising the steps of:

1. A method comprising: (1) obtaining a free-flowing fluid of tranexamic acid; (2) mixing the free-flowing fluid of tranexamic acid with ibuprofen, or with a free-flowing fluid of ibuprofen obtained by adding a solvent or by heating; and (3) forming crystals from the mixture.

9. The method according to claim 7 or 8, further comprising drying the mixture obtained in step (3).

10. The method according to any one of claims 7 to 9, wherein the solvent added to the ibuprofen is selected from ethanol, acetone, dimethylsulfoxide, or a mixture of one or more thereof.

11. The method according to any one of claims 8 to 10, wherein the flowable, fluid tranexamic acid is obtained by adding water to tranexamic acid.

12. The method according to any one of claims 7 to 11, further comprising adding a lubricant to the mixture obtained in step (2) according to claim 7 or 8 and mixing the mixture.

13. The method according to claim 12, wherein the lubricant is selected from the group consisting of magnesium- or calcium-containing organic acids having 16 to 18 carbon atoms, talc, sucrose fatty acid esters, and hydrogenated fats and oils.

14. The method according to any one of claims 7 to 13, wherein the mixing in step (2) according to claim 7 or 8 is wet granulation.

15. The method according to claim 14, wherein the wet granulation is mortar granulation, agitation granulation, fluidized bed granulation, rolling granulation, or extrusion granulation.

16. A method for producing a crystal of ibuprofen and tranexamic acid, comprising the steps of:

1. A method comprising: (1) adding ibuprofen and tranexamic acid to a solvent to obtain a solution or dispersion; (2) spraying and drying the obtained solution or dispersion; or allowing the solution obtained in step (1) to stand, filtering the product obtained after standing, and drying the product.

17. In step (2), the solution or dispersion is sprayed to form granules, and then dried.

17. The method of claim 16.

18. 18. The method of claim 16 or 17, wherein the solvent is ethanol, water, or a mixture thereof.

19. The method according to any one of claims 7 to 18, wherein the compounding ratio of ibuprofen to tranexamic acid is 1 part by weight:10 parts by weight to 10 parts by weight:1 part by weight.

20. A crystal obtained by the method according to any one of claims 7 to 19.

21. A composition comprising the crystal according to any one of claims 1 to 6 or the crystal according to claim 20.

22. A composition comprising the crystal described in claim 20, in which ibuprofen and tranexamic acid are present in a molar ratio of 1:1, said crystal comprising 80 mol% or more of the lesser amount (moles) of the raw materials ibuprofen and tranexamic acid.

23. 23. The composition of claim 21 or 22, which is a solid formulation.

24. 24. The composition of claim 23, wherein the solid formulation is a tablet.

25. The composition according to any one of claims 21 to 24, which is an anti-inflammatory, antipyretic, analgesic or cold remedy.

Citation Information

Patent Citations

  • Antipyretic and analgesic agent

    JP1997048728A

  • Pharmaceutical preparation and method for producing the same

    JP2007284423A

  • Co-crystal pharmaceutical compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

    JP2007507554A

  • Expansion-suppressing method for solid formulation containing ibuprofen and tranexamic acid

    JP2008295731A

  • Solid preparation containing ibuprofen and tranexamic acid

    JP2009203218A